leflunomide has been researched along with Cardiovascular Diseases in 5 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with leflunomide or low doses of glucocorticoids were not associated with severe course in our cohort." | 2.82 | COVID-19 among patients with giant cell arteritis: a single-centre observational study from Slovenia. ( Hočevar, A; Ješe, R; Kramarič, J; Rotar, Ž; Tomšič, M, 2022) |
| "Patients with treated hypertension should be monitored regularly when conventional NSAIDs or COX-2 inhibitors are administered." | 2.41 | Cardiovascular risk profile of antirheumatic agents in patients with osteoarthritis and rheumatoid arthritis. ( Dijkmans, BA; Nurmohamed, MT; van Halm, VP, 2002) |
| "Our study showed that treatment of early rheumatoid arthritis with a combination regime of traditional DMARDs is highly effective in controlling disease activity as well as cardiovascular risk." | 1.39 | Early, structured disease modifying anti-rheumatic drug (DMARD) therapy reduces cardiovascular risk in rheumatoid arthritis--a single centre study using non-biologic drugs. ( Biswas, M; Chatterjee, S; Ghosh, A; Ghosh, S; Sarkate, P, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kramarič, J | 1 |
| Ješe, R | 1 |
| Tomšič, M | 1 |
| Rotar, Ž | 1 |
| Hočevar, A | 1 |
| Barbarroja, N | 1 |
| Ruiz-Ponce, M | 1 |
| Cuesta-López, L | 1 |
| Pérez-Sánchez, C | 1 |
| López-Pedrera, C | 1 |
| Arias-de la Rosa, I | 1 |
| Collantes-Estévez, E | 1 |
| Chatterjee, S | 1 |
| Sarkate, P | 1 |
| Ghosh, S | 1 |
| Biswas, M | 1 |
| Ghosh, A | 1 |
| Nurmohamed, MT | 1 |
| van Halm, VP | 1 |
| Dijkmans, BA | 1 |
| Grove, ML | 1 |
3 reviews available for leflunomide and Cardiovascular Diseases
| Article | Year |
|---|---|
COVID-19 among patients with giant cell arteritis: a single-centre observational study from Slovenia.
Topics: Cardiovascular Diseases; COVID-19; Giant Cell Arteritis; Glucocorticoids; Humans; Hypertension; Lefl | 2022 |
Nonalcoholic fatty liver disease in inflammatory arthritis: Relationship with cardiovascular risk.
Topics: Arthritis, Psoriatic; Arthritis, Rheumatoid; Biological Products; Cardiovascular Diseases; Heart Dis | 2022 |
Cardiovascular risk profile of antirheumatic agents in patients with osteoarthritis and rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Cardiovascular | 2002 |
2 other studies available for leflunomide and Cardiovascular Diseases
| Article | Year |
|---|---|
Early, structured disease modifying anti-rheumatic drug (DMARD) therapy reduces cardiovascular risk in rheumatoid arthritis--a single centre study using non-biologic drugs.
Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Cardiovasc | 2013 |
US Food and Drug Administration gets it right.
Topics: Cardiovascular Diseases; Chemical and Drug Induced Liver Injury; Cyclooxygenase 2; Drug Approval; Hu | 2002 |